Richard Gawel

Motor function improved with a favorable safety profile for patients with Parkinson’s disease who used tavapadon while receiving oral levodopa, according to a study published in JAMA Neurology.This research “was prompted by a long-standing and very practical clinical need,” Zoltan Mari, MD, FAAN, Ruvo Family (Endowed) Chair and Director of the Parkinson’s Disease &

Motor function improved with a favorable safety profile for patients in the early stages of Parkinson’s disease using tavapadon, according to a study published in JAMA Neurology.Long-term use of oral levodopa, which is the current initial treatment, has been linked to motor complications, Angelo Antonini, MD, PhD, professor, Padova Neuroscience Center, University of Padova, and colleagues

Although the prevalence of MS more than doubled in England between 2000 and 2020, survival rates improved, according to a research letter published in JAMA Neurology. Additionally, the researchers wrote, disparities in mortality have emerged.

CHICAGO — mproving the gap between biological and chronological ages decreased risk for stroke and improved brain health, according to a poster presented at the American Academy of Neurology Annual Meeting. “It’s exciting to think that working to modify our biological age could be a pathway to preserving brain health,” Cyprien Rivier, MD, MSc, instructor, department of

The FDA approved dupilumab to treat children aged 2 to 11 years with chronic spontaneous urticaria and persistent symptoms despite H1 antihistamine treatment, according to a company press release. The FDA’s decision expands the April 2025 approval of dupilumab (Dupixent, Regeneron/Sanofi) for chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 years and older.

Since President Donald J. Trump’s executive order to increase access to psychedelics and other alternative therapies for mental health, HHS has announced new regulatory actions and funding to support the development of these drugs. “While there are a number of available therapies for various illnesses such as depression, substance use disorder and PTSD, many people do not respond well to these

CHICAGO — Patients with Alzheimer’s disease on amyloid-targeting therapy had less cognitive decline when their baseline amyloid burden was lower, according to a poster presented at the American Academy of Neurology Annual Meeting.“This is a dataset of people who had at least 6 months of treatment with the donanemab or 12 months of treatment with the lecanemab,” Ahlanna

CHICAGO — By launching virtual visits with remote neurologists, Geisinger Health increased new visits by 80% and reduced its patient backlog by 72%, according to a poster presented at the American Academy of Neurology Annual Meeting. “We’re in a rural area in Pennsylvania. We’re finding trouble recruiting and retaining neurologists,” Neil R. Holland, MD, chair of

Individuals in middle age with higher levels of plasma amyloid-beta 42, amyloid-beta 40 and phosphorylated-tau 217 demonstrated worse cognitive performance and accelerated cognitive decline, according to data published in The Lancet.“We already know that Alzheimer’s disease pathophysiology can begin decades before symptoms arise,” Xiaqing Jiang, PhD, a postdoctoral scholar in

Patients with early Alzheimer’s disease treated with diranersen experienced slower cognitive decline and greater reductions in tau compared with placebo, according to data presented at the Alzheimer’s Association International Conference.Diranersen (BIIB080, Biogen) is an investigational antisense oligonucleotide therapy that reduces tau production by targeting microtubule-associated